Impact of primary glaucoma on health-related quality of life in China: the handan eye study.
EQ-5D
Glaucoma
Health-Related Quality of Life
Visual function quality of life
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
received:
29
11
2022
accepted:
17
08
2023
medline:
18
9
2023
pubmed:
15
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
We assessed health-related quality of life (HRQOL) and its determinants among rural glaucoma participants compared to age-matched normal controls in the population-based Handan Eye Study (HES), in rural Yongnian County, northern China. We enrolled 99 adults with glaucoma (mean age 63.0 ± 11.0 years), including primary open-angle glaucoma (POAG, n = 67) and primary angle-closure glaucoma (PACG, n = 32) and 102 controls (mean age 58.5 ± 5.3 years) with normal visual acuity and visual field and no history of glaucoma. Results of ophthalmic examinations and socioeconomic data were recorded. HRQOL was measured using the EQ-5D (converted to utility valves, UVs), and visual function (VF) and vision-related quality of life (VRQOL) were evaluated using the visual function-quality of life (VF-QOL) instrument. EQ-5D and VF-QOL scores. The mean UVs, VF, and VRQOL scores for glaucoma cases were 0.98 ± 0.04, 87.9 ± 15.2, and 95.5 ± 12.8, respectively, significantly worse than VF (94.4 ± 4.4) and VRQOL (100.0 ± 0.0) among controls, even after adjusting for age, gender, educational level, and family income (P = 0.015, P = 0.033). UVs were significantly lower among glaucoma participants with impaired VRQOL (55.4 ± 11.5) compared to those with normal VRQOL scores (99.1 ± 2.8) (UVs: 0.92 ± 0.08 vs. 0.99 ± 0.03, P = 0.036), also after adjustment for age and family income (P = 0.006). Participants with PACG had significantly lower VF and VRQOL scores compared to POAG (77.8 ± 21.4 vs. 92.9 ± 6.8, P < 0.001; 89.0 ± 18.1 vs. 98.7 ± 7.5, P < 0.001). Participants with glaucoma have worse visual function and related quality of life compared to age-matched normal population controls. Participants with PACG have lower VF and VRQOL compared to those with POAG. UVs can be used for cost-effectiveness research and to support public health strategies for glaucoma in rural China.
Sections du résumé
BACKGROUND
BACKGROUND
We assessed health-related quality of life (HRQOL) and its determinants among rural glaucoma participants compared to age-matched normal controls in the population-based Handan Eye Study (HES), in rural Yongnian County, northern China.
METHODS
METHODS
We enrolled 99 adults with glaucoma (mean age 63.0 ± 11.0 years), including primary open-angle glaucoma (POAG, n = 67) and primary angle-closure glaucoma (PACG, n = 32) and 102 controls (mean age 58.5 ± 5.3 years) with normal visual acuity and visual field and no history of glaucoma. Results of ophthalmic examinations and socioeconomic data were recorded. HRQOL was measured using the EQ-5D (converted to utility valves, UVs), and visual function (VF) and vision-related quality of life (VRQOL) were evaluated using the visual function-quality of life (VF-QOL) instrument.
PRIMARY AND SECONDARY OUTCOME MEASURES
METHODS
EQ-5D and VF-QOL scores.
RESULTS
RESULTS
The mean UVs, VF, and VRQOL scores for glaucoma cases were 0.98 ± 0.04, 87.9 ± 15.2, and 95.5 ± 12.8, respectively, significantly worse than VF (94.4 ± 4.4) and VRQOL (100.0 ± 0.0) among controls, even after adjusting for age, gender, educational level, and family income (P = 0.015, P = 0.033). UVs were significantly lower among glaucoma participants with impaired VRQOL (55.4 ± 11.5) compared to those with normal VRQOL scores (99.1 ± 2.8) (UVs: 0.92 ± 0.08 vs. 0.99 ± 0.03, P = 0.036), also after adjustment for age and family income (P = 0.006). Participants with PACG had significantly lower VF and VRQOL scores compared to POAG (77.8 ± 21.4 vs. 92.9 ± 6.8, P < 0.001; 89.0 ± 18.1 vs. 98.7 ± 7.5, P < 0.001).
CONCLUSION
CONCLUSIONS
Participants with glaucoma have worse visual function and related quality of life compared to age-matched normal population controls. Participants with PACG have lower VF and VRQOL compared to those with POAG. UVs can be used for cost-effectiveness research and to support public health strategies for glaucoma in rural China.
Identifiants
pubmed: 37710186
doi: 10.1186/s12886-023-03106-w
pii: 10.1186/s12886-023-03106-w
pmc: PMC10503180
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
377Subventions
Organisme : Program of Health Policy for Blindness Prevention from Ministry of Health the People's Republic of China
ID : No. 2006-10903
Organisme : Zhejiang Health Innovative Talents Project
ID : No. 2016025
Organisme : National Basic Research Program of China
ID : 2007CB512201
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Curr Eye Res. 2019 Apr;44(4):436-441
pubmed: 30433828
Am J Ophthalmol. 1998 Oct;126(4):515-23
pubmed: 9780096
Invest Ophthalmol Vis Sci. 2011 Oct 21;52(11):8250-7
pubmed: 21896871
Ophthalmic Epidemiol. 2007 May-Jun;14(3):119-26
pubmed: 17613846
Br J Ophthalmol. 2009 Jul;93(7):871-4
pubmed: 19208679
Can J Ophthalmol. 2014 Aug;49(4):320-5
pubmed: 25103647
J Glaucoma. 2015 Sep;24(7):508-14
pubmed: 25415642
Menopause. 2018 Oct;25(10):1116-1123
pubmed: 29787481
Ophthalmology. 2008 Jun;115(6):941-948.e1
pubmed: 17997485
Menopause. 2004 Jan-Feb;11(1):69-77
pubmed: 14716185
Acta Ophthalmol Scand. 2006 Jun;84(3):363-71
pubmed: 16704699
Eye (Lond). 2012 Oct;26(10):1295-301
pubmed: 22766537
BMJ Open. 2019 Mar 23;9(3):e024209
pubmed: 30904848
Am J Ophthalmol. 1998 Oct;126(4):487-97
pubmed: 9780093
Ophthalmology. 2015 Jan;122(1):72-8
pubmed: 25283061
Am J Ophthalmol. 2018 Nov;195:1-7
pubmed: 30053479
Curr Med Res Opin. 2008 Jun;24(6):1763-70
pubmed: 18559164
J Glaucoma. 2008 Oct-Nov;17(7):552-7
pubmed: 18854732
Ophthalmic Epidemiol. 2009 Mar-Apr;16(2):115-27
pubmed: 19353400
Ophthalmology. 2015 Oct;122(10):2010-21
pubmed: 26319441
Arch Ophthalmol. 2000 Aug;118(8):1105-11
pubmed: 10922206
Ophthalmic Epidemiol. 2014 Apr;21(2):66-78
pubmed: 24568628
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2782-8
pubmed: 16799014
Value Health. 2011 Sep-Oct;14(6):900-6
pubmed: 21914512
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Lancet Glob Health. 2019 Jul;7(7):e968-e978
pubmed: 31122906
Qual Life Res. 2012 Feb;21(1):155-60
pubmed: 21505881
Acta Ophthalmol. 2014 Dec;92(8):e637-43
pubmed: 24836295
J Glaucoma. 1994 Summer;3 Suppl 1:S19-31
pubmed: 19920584
Br J Ophthalmol. 2001 Nov;85(11):1277-82
pubmed: 11673287
Indian J Ophthalmol. 2015 Jan;63(1):20-4
pubmed: 25686057
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Value Health. 2018 Nov;21(11):1330-1337
pubmed: 30442281
BMC Health Serv Res. 2011 Mar 26;11:67
pubmed: 21439077
Invest Ophthalmol Vis Sci. 2008 May;49(5):1907-15
pubmed: 18436824
JAMA Ophthalmol. 2014 Mar;132(3):298-303
pubmed: 24481323
Invest Ophthalmol Vis Sci. 2011 Nov 07;52(12):8672-9
pubmed: 21908580
Value Health. 2014 Jul;17(5):597-604
pubmed: 25128053